or Connect
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › CBIS - Cannabis Science
New Posts  All Forums:Forum Nav:

CBIS - Cannabis Science - Page 11  

post #201 of 1303
Thread Starter 
CBIS up 61 %
post #202 of 1303
Thread Starter 
post #203 of 1303
Been watching this off and on for a while now. I jumped in this morning for a small position.
post #204 of 1303
took a small position today also.....my lotto
post #205 of 1303
I also opened a tiny position to test the waters
post #206 of 1303
how long are you guys looking to hold for? until more news comes out, or long term? thinking about taking a small position
post #207 of 1303
I increased my position today with some of the cheapies.
After doing more DD, this looks pretty interesting. Government involvement is always good.
Live interview is scheduled for Monday. Glad I got in before that.
I will prob hold half my position long term and other half wait and see?...depends.
Looks like it has hit bottom here at 10-11ish. Lots of shares lined up to buy at .10....so i jumped in JUST above.
post #208 of 1303
Quote:
Originally Posted by RetireYoung View Post
how long are you guys looking to hold for? until more news comes out, or long term? thinking about taking a small position
Penny stocks in my experience always moves on news. I comfortably sell a good portion of it on PR and usually move on to the next stock. From a long term view perspective, if I were to keep any, then it would be after I've recovered my initial investment plus my initial target $ goal. I'd simply let the rest ride and take profits when I needed them or saw good opportunity. Just my 2c's.
post #209 of 1303
Live interview tomorrow at 8pm.
might be interesting trading
post #210 of 1303
might be a huge gap today....L2 looks interesting
post #211 of 1303

Posted Today

http://www.tradingmarkets.com/news/p...--1009779.html

News Today:

COLORADO SPRINGS, Colo., Jun 28, 2010 -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, reports an important milestone for the continued validation of medical cannabis, as UK-based GW Pharmaceuticals (http://gwpharm.com/) receives $15 million milestone payment from Bayer. This payment to GW is based on the UK Government's approval of the "First Prescription Cannabis Medicine", GW Pharmaceuticals Sativex(R), an "Oromucosal Spray" tincture for the treatment of spasticity due to Multiple Sclerosis (MS). Analysts at Piper Jaffray forecast that peak sales could reach $180 million in Europe and Canada combined. Presently, GW has a market capitalization of over $260 million.

Richard Cowan, Cannabis Science CFO noted, "Bayer's $15 million 'milestone payment' to GW clearly puts the world on notice that pharmaceutical cannabis is now 'mainstream'. Previously, the US FDA granted GW a Phase III IND for Sativex, and a Phase IIb/III trial for cancer pain is currently ongoing. GW has also received an 18 million dollar licensing fee from Otsuka for the US rights, and they also received millions more from licensing fees from Almiral of Spain for the European rights outside of the UK. The licensees also pay for the work necessary for regulatory approval. Clearly, Big Pharma recognizes the explosive growth this industry is experiencing and does not want to be left behind. Obviously, licensing of products and territories -- which is common for new biotech companies -- suggests another important way Cannabis Science can move forward with its financing objectives."

Dr. Robert Melamede, PhD., Cannabis Science President and CEO, said, "The UK Government's approval of Sativex(R) is long overdue. MS patients in the UK and around the world have long used cannabis to get relief from pain and spasticity. We hope, given this recognition of the medical value of cannabis, that the UK government will stop arresting patients who use the plant to deal with their pain and suffering, whatever their medical problems may be. Also, we think this approval should lead to faster regulatory action in the future for medicines derived from whole plant extracts from cannabis. Given the millennia of use that proves the safety of cannabis, and its widespread medical use by millions of people for a great variety of problems today, we hope that the approval of Sativex(R) will lead to the fast-tracking of other whole cannabis extracts by the regulatory authorities.
post #212 of 1303
CBIS had a fantastic live interview last night at 8pm
post #213 of 1303
Good news out and yet no movement. The whole market is taking a beating today. It's such a bad day to release the news!

Cannabis Science Begins Expansion of Production and Research at Montana Pain Management
"The Proven Ability to Address the Developing Medical Cannabis Market at a National Level"

COLORADO SPRINGS, Colo., Jun 29, 2010 (GlobeNewswire via COMTEX) -- Cannabis Science, Inc. (CBIS 0.10, -0.01, -7.46%) , a pioneering U.S. biotech company developing pharmaceutical cannabis products, reports that it has begun the process of expanding the internal production and research capabilities of Missoula medical cannabis provider, Montana Pain Management (MPM), which Cannabis Science acquired earlier this month.

Rick Rosio, President of MPM, explained, "Our clients deserve quality and compassion, and the union of MPM and Cannabis Science is crucial to ensuring that our patients have consistent access to the safest and most effective cannabis therapeutics."

Recent bans and moratoriums in Montana have forced the closing of many cannabis providers across the state, leaving patients worried about how to legally acquire their supply of medicine. The instability surrounding medical cannabis has created problems for many of Montana's ill, forcing them into situations where safe access is impossible.

"This is about education and quality control," says Rosio. "By being compassionate, honest, and transparent we hope to build a lasting positive relationship with Missoula and all of Montana. The ability to track all produced cannabis and strict checks and balances insures that any community or state agency that is looking for ways to provide medical cannabis in their communities can confidently look at the solutions that Cannabis Science is now able to offer."

Dr. Robert Melamede PhD, Cannabis Science President and CEO, added, "Our production staff has begun the process of expanding the internal production of cannabis at MPM's facilities in Missoula. This process will allow MPM to expand its patient base by 100 new clients each month and provide the necessary in-house production of advanced medical cannabis genetics to further Cannabis Science's objectives in developing pharmaceutical applications for medical cannabis. We are pleased that Montana officials are working with Rick Rosio to develop policies that protect patients and assure that they have access to the medicine they need."

Richard Cowan, Cannabis Science CFO, explained, "Increasing the output from the internal production facilities is critical to a swift and aggressive positioning in the developing national medical cannabis industry. With the proven abilities of MPM's agricultural staff, combined with the analytical capabilities of our scientists and commercial production staff, Cannabis Science now has the proven ability to address the developing medical cannabis market at a national level as more states enact compassionate policies."

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Cannabis Science, Inc.

CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.comInvestor Relations
Mark J. Friedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com



http://www.marketwatch.com/story/can...k=MW_news_stmp
post #214 of 1303
Thread Starter 
post #215 of 1303
Thread Starter 
CBIS up 18.8 %
post #216 of 1303
Thread Starter 
post #217 of 1303
Thread Starter 
CBIS up 28 %
post #218 of 1303
This has been floating around the 8-9 for awhile...thoughts anyone? This company seems to be progressing in terms of development.
post #219 of 1303
Ten sessions it has touched under .10 since the pps field day last summer (bless those days!) and 6 or 7 are from the last ten sessions, not like it's been floating around .08-.09 for a while at all. Chart looks atrocious IMO and I'm not sure what their share structure is but all that recent volume might just be dilution, I would check that before dipping even a toe in these waters. Also there are probably lots of blazers who come here any time it has a good day to tout CBIS, just be very prudent here.
post #220 of 1303

Harvest Time

Quote:
Originally Posted by rando View Post
Ten sessions it has touched under .10 since the pps field day last summer (bless those days!) and 6 or 7 are from the last ten sessions, not like it's been floating around .08-.09 for a while at all. Chart looks atrocious IMO and I'm not sure what their share structure is but all that recent volume might just be dilution, I would check that before dipping even a toe in these waters. Also there are probably lots of blazers who come here any time it has a good day to tout CBIS, just be very prudent here.


I agree about the "D" word. I think the closer we get to Sept 2010 the closer our PPS will reflect the true value of this stock!!!

Let it settle.....
New Posts  All Forums:Forum Nav:
  Return Home
  Back to Forum: Penny Stocks
This thread is locked  
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › CBIS - Cannabis Science